Friday, September 29, 2017 12:51:14 PM
The idea that the FDA would require a Phase 1 for cellulose is absurd. It's in our food, it's in our eye drops, it's in the lips of people who get those dumb lip plumper injections.
If the data from the old P1/2 is not sufficient based on the protocols when it was conducted 17 years ago the FDA will absolutely require a safety phase be conducted. Its not just cellulose its the combination of everything that's part of the treatment.
The idea that the FDA would require a Phase 1 safety study on people literally dying of pancreatic cancer is outrageous. FDA: Hi, before you die we'd like to inject you with CiaB. Oh, no, we won't activate it to see if it works, we just want to see if you get a rash at the injection site...
As stupid as it sounds every treatment goes through FDA protocols. PMCB is no different.
If the data from the old P1/2 is not sufficient based on the protocols when it was conducted 17 years ago the FDA will absolutely require a safety phase be conducted. Its not just cellulose its the combination of everything that's part of the treatment.
The idea that the FDA would require a Phase 1 safety study on people literally dying of pancreatic cancer is outrageous. FDA: Hi, before you die we'd like to inject you with CiaB. Oh, no, we won't activate it to see if it works, we just want to see if you get a rash at the injection site...
As stupid as it sounds every treatment goes through FDA protocols. PMCB is no different.
Recent PMCB News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:16:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:19:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/17/2026 07:49:54 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/09/2026 01:40:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 10:02:46 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/27/2026 10:05:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/18/2025 10:04:23 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 12/15/2025 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2025 10:07:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2025 10:00:25 PM
- PharmaCyte Biotech stock surges following profitable exit from Femasys investment • IH Market News • 11/25/2025 03:56:47 PM
- PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment • Business Wire • 11/25/2025 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:32:29 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/18/2025 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 08:05:33 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/06/2025 09:08:43 PM
